Table 1 Demographic data and clinical features of the patients enrolled in the analysis (n = 155)

Male sex, n (%)

126 (81.3)

Age (years)

56.21 ± 7.57 (56.00)

35.00–73.00

Diabetes mellitus, n (%)

31 (20)

Etiology of cirrhosis, n (%)

 HBV

70 (45.2)

 HCV

53 (34.2)

Alcoholic

13 (8.4)

 Alcoholic with HBV & HCV

6 (3.9)

 HBV and HCV

6 (3.9)

 Other

7 (4.5)

MELD score

13.19 ± 7.30 (11.00)

5.00–40.00

Alpha-fetoprotein (ng/mL)

1524 ± 14,172.24 (16.66)

0.97–170,961.00

GRWR

1.07 ± 0.28 (1.02)

0.55–2.02

Operative time (min)

423.43 ± 87.44 (415.00)

265.00–690.00

Blood loss (ml)

2939.03 ± 3238.67 (1850.00)

200.00–23,000.00

Tumor characteristic

 Image tumor number

2.11 ± 2.18 (1.0)

0.00–10.00

 Image max tumor size (cm)

2.83 ± 2.24 (2.3)

0.00–14.50

 Image total tumor size (cm)

4.53 ± 4.21 (3.2)

0.00–25.40

 Image vascular invasion, n (%)

13 (8.4)

 Pathology tumor number

2.54 ± 2.19 (2.0)

0.00–14.00

 Pathology max tumor size (cm)

3.53 ± 2.50 (3.0)

0.00–16.10

 Pathology total tumor size (cm)

5.62 ± 4.45 (4.0)

0.00–22.80

 Pathology vascular invasion, n (%)

24 (15.5)

 Combined cholangiocarcinoma, n (%)

7 (4.5)

Image and pathology compatible, n (%)

129 (83.2)

 Image—Met Milan criteria, n (%)

99 (63.9)

 Image—beyond Milan criteria, n (%)

56 (36.1)

 Pathology—Met Milan criteria, n (%)

77 (49.7)

 Pathology—beyond Milan criteria, n (%)

78 (50.3)

Outcome

 HCC recurrent, n (%)

38 (24.5)

 Mortality, n (%)

44 (28.4)

Follow up (year)

4.44 ± 2.35 (4.20)

0.27–12.09